S4318 A Rare Case of Synchronous Esophageal Squamous Cell Carcinoma: Implications of Molecular Testing for Prognosis, Clonality, and Targeted Therapy

Introduction: Esophageal squamous cell carcinoma is far more common in Asia, while esophageal adenocarcinoma is more common in the U.S. Synchronous squamous cell carcinoma (SSCC) is a rare subtype involving multiple primary tumors, separated by normal mucosa, arising simultaneously in the esophagus. It is particularly infrequent in Western countries and may be associated with different risk factors and worse long-term survival than solitary squamous cell carcinoma (SCC). We present a rare case of double SSCC whereby molecular profiles of both tumors were analyzed using next generation sequencing (NGS), highlighting the growing importance of precision oncology. Case Description/Methods: A 72-year-old man with history of alcohol, opioid, and chronic tobacco use disorder presented with worsening dysphagia. A diagnostic esophagogastroduodenoscopy showed a circumferential friable mass lesion in the mid-esophagus and a distinctly separate semi-circumferential ulcerated lesion in the distal esophagus. Biopsies confirmed both lesions as moderately to poorly differentiated SCC and illustrate the positive immunohistochemistry analyses of these lesions for PD-L1. NGS revealed a combined positive score of 1 and 20 for the proximal and distal lesions, respectively, in addition to stable microsatellite status, suggestive of poor response to immunotherapy. Both tumors shared typical driver mutations in TP53, CDKN2A/B, and TET2 genes, whereas some non-driver mutations (ASXL1, NFKB1A, NSD3) were only detected in the proximal but not the distal tumor. The patient was diagnosed with T3N2M0 disease and underwent neoadjuvant chemoradiation. However, he developed significant complications and was not a candidate for further active therapy. Discussion: NGS provided important insight into characterizing the intra-tumor heterogeneity in this very rare case of SSCC. Common driver mutations were found in both tumors, supporting the “field cancerization” theory in which widespread epithelial injury from carcinogens like chronic tobacco and alcohol use can lead to a pre-malignant field with genetic instability. However, the presence of additional mutations in the proximal lesion supports the idea of a branched common progenitor clone. Evidence of these 2 models suggest that while the tumors are not metastatic, they are also not completely independent. Therefore, NGS offers a more comprehensive understanding of tumor clonality with a particularly critical impact on the actionability and development of targeted therapies in esophageal SCC.

Authors

Publication Details

Journal
The American Journal of Gastroenterology
Published
2025-10-01
DOI
https://doi.org/10.14309/01.ajg.0001144732.50690.ef
Primary Topic
Esophageal Cancer Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

S4318 A Rare Case of Synchronous Esophageal Squamous Cell Carcinoma: Implications of Molecular Testing for Prognosis, Clonality, and Targeted Therapy

Felicia Lee, H. Christian Weber, Michael Waisberg, Vanessa Avalone et al.
The American Journal of Gastroenterology
Esophageal Cancer Research and Treatment
article

S4318 A Rare Case of Synchronous Esophageal Squamous Cell Carcinoma: Implications of Molecular Testing for Prognosis, Clonality, and Targeted Therapy

Felicia Lee, H. Christian Weber, Michael Waisberg, Vanessa Avalone, Marya Pulaski
article en

Abstract

Introduction: Esophageal squamous cell carcinoma is far more common in Asia, while esophageal adenocarcinoma is more common in the U.S. Synchronous squamous cell carcinoma (SSCC) is a rare subtype involving multiple primary tumors, separated by normal mucosa, arising simultaneously in the esophagus. It is particularly infrequent in Western countries and may be associated with different risk factors and worse long-term survival than solitary squamous cell carcinoma (SCC). We present a rare case of double SSCC whereby molecular profiles of both tumors were analyzed using next generation sequencing (NGS), highlighting the growing importance of precision oncology. Case Description/Methods: A 72-year-old man with history of alcohol, opioid, and chronic tobacco use disorder presented with worsening dysphagia. A diagnostic esophagogastroduodenoscopy showed a circumferential friable mass lesion in the mid-esophagus and a distinctly separate semi-circumferential ulcerated lesion in the distal esophagus. Biopsies confirmed both lesions as moderately to poorly differentiated SCC and illustrate the positive immunohistochemistry analyses of these lesions for PD-L1. NGS revealed a combined positive score of 1 and 20 for the proximal and distal lesions, respectively, in addition to stable microsatellite status, suggestive of poor response to immunotherapy. Both tumors shared typical driver mutations in TP53, CDKN2A/B, and TET2 genes, whereas some non-driver mutations (ASXL1, NFKB1A, NSD3) were only detected in the proximal but not the distal tumor. The patient was diagnosed with T3N2M0 disease and underwent neoadjuvant chemoradiation. However, he developed significant complications and was not a candidate for further active therapy. Discussion: NGS provided important insight into characterizing the intra-tumor heterogeneity in this very rare case of SSCC. Common driver mutations were found in both tumors, supporting the “field cancerization” theory in which widespread epithelial injury from carcinogens like chronic tobacco and alcohol use can lead to a pre-malignant field with genetic instability. However, the presence of additional mutations in the proximal lesion supports the idea of a branched common progenitor clone. Evidence of these 2 models suggest that while the tumors are not metastatic, they are also not completely independent. Therefore, NGS offers a more comprehensive understanding of tumor clonality with a particularly critical impact on the actionability and development of targeted therapies in esophageal SCC.

The American Journal of GastroenterologyVol. 120(10S2)
Openalex Percentile: Top 48%
Esophageal Cancer Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.